ROIV Roivant Sciences Ltd
Company Analysis
Latest News
🟢 Roivant Sciences is trading 4.7% up today amid continued biotech momentum
Roivant Sciences is trading at $38.55 (+4.7%) in after-hours as the stock extends its multi-week uptrend amid positive sentiment toward its biotech...
Roivant Sciences Director Sells $56 Million in Shares, Retains Large Stake
Roivant Sciences Director Keith S. Manchester sold over $56.4 million in company stock according to filings reported on July 1, 2026. The transactions...
Roivant President Sells $34M in Stock Following Index Removal
Roivant Sciences President and Chief Investment Officer Mayukh Sukhatme sold 1,000,000 shares on June 30, 2026. The total transaction value reached...
🟢 ROIV extends move to 5.0% up
ROIV is trading at $33.83, up 5.0% versus the comparison close of $32.21 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 ROIV is trading 4.24% up today following Moderna settlement and positive pipeline updates
ROIV is trading at $33.58 (4.24% up) following a strong follow-through from the prior session and continued optimism around recent company developments. •...
🟢 Roivant Sciences Ltd is trading 4% up today on improved risk sentiment
Roivant Sciences Ltd is trading 4% up today at $29.55 on improved risk sentiment, tracking broader gains across major U.S. indices. • The advance occurs on...
Roivant Secures $950M Moderna Settlement, Eyes Major 2026 Clinical Data
Roivant Sciences expects a $950 million upfront payment from Moderna in July 2026. This payment is part of a $2.25 billion global settlement resolving patent...
Jefferies buys $76.3M Roivant stake, as institutional confidence grows
Jefferies Financial Group purchased 3,514,833 shares of Roivant Sciences in a fourth-quarter filing. The investment is valued at approximately $76.3...
🔴 ROIV is trading 4.3% down today on profit-taking after post-earnings surge
ROIV is trading 4.3% down today at $31.03 as the stock undergoes normal profit-taking and consolidation following a sharp rally in the prior session. • Shares...
🟢 ROIV is trading 11.2% up today on Q4 results and $2.25B Moderna settlement
ROIV is trading at $31.36 (+11.2%) following Q4 FY2026 results highlighted by a $2.25 billion global patent litigation settlement with Moderna. • The...
🟢 ROIV is trading 8.3% up today after a GAAP earnings beat fueled by a $770.2 million Moderna settlement gain
ROIV is trading 8.3% up at $30.54 following its Q4 earnings release, which featured a significant GAAP EPS beat despite weaker-than-expected revenue. The...
🟢 ROIV is trading 12% up today on a $2.25B Moderna settlement and Q4 earnings
ROIV is trading about 12% up at $31.50 in pre-market after reporting a massive $770.2M pre-tax gain from a $2.25B patent settlement with Moderna. • The...
Roivant's fourth quarter 2026 EPS beats on a $770.2M litigation gain, while key pipeline assets advance
Roivant reported fourth-quarter fiscal 2026 revenue of $2.52 million, below analyst estimates, while GAAP earnings per share from continuing operations was...
Roivant Sciences Reports 2026 Results, Eyes Q3 FDA Decision for Brepocitinib
Roivant Sciences reported financial results for the fourth quarter and fiscal year ended March 31, 2026. Analysts projected a loss per share between $0.29 and...
Roivant Sciences Ltd Q1 2026 Earnings Preview: What Analysts Expect on May 20, 2026
Wall Street expects Roivant Sciences to report consensus revenue of $3.68 million and an EPS of -$0.38, with the current stock price of $29.29 trading...
🟢 ROIV is trading 4.3% up today with no clear catalyst yet
ROIV is trading 4.3% up at $30.55 in pre-market action, showing strength despite a lack of immediate fundamental catalysts. • Shares are rebounding from a...